E. Stavrinidis

Randomized Phase III Study of 1 Month Versus 1 Year of Adjuvant High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma

Dimitrios Pectasides, Urania Dafni, Dimitrios Bafaloukos et al. · Journal of Clinical Oncology · 2009 · 122 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +16

Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study

Vassilis Georgoulias, Ch. Kouroussis, Athina Agelidou et al. · British Journal of Cancer · 2004 · 59 citations · Full text

Medicine, Oncology, Pharmacology +15

Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: Final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up

Alexander D. Rapidis, Miltiades Trichas, E. Stavrinidis et al. · Oral Oncology · 2006 · 49 citations

Medicine, Oncology, Chemotherapy +12

Docetaxel plus cisplatin versus docetaxel plus gemcitabine chemotherapy in advanced non-small cell lung cancer: A preliminary analysis of a multicenter randomized phase II trial

Vassilis Georgoulias, E. Papadakis, Athanasios Alexopoulos et al. · European Journal of Cancer · 1999 · 43 citations

Medicine, Oncology, Pharmacology +13

Salvage Treatment of Metastatic Breast Cancer with Docetaxel and Carboplatin

D. Mavroudis, A. Alexopoulos, Nikolaos Malamos et al. · Oncology · 2003 · 20 citations

Medicine, Oncology, Pharmacology +17